Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen



Status:Completed
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:2/24/2018
Start Date:December 2011
End Date:June 2014

Use our guide to learn which trials are right for you!

A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1

The main purpose of this study was to compare the effects on bones of the following two drug
combinations:

- maraviroc (MVC), emtricitabine (FTC), plus darunavir/ritonavir (DRV/r)

- tenofovir (TDF) plus emtricitabine (FTC) plus darunavir/ritonavir (DRV/r)

Additional study objectives were the following:

- To see how the drug combinations affect the brain and kidneys.

- To see how well the drug combinations lower the HIV viral load.

- To see how safe the drug combinations are, how well people are able to take the study
drug combinations, and how well their immune systems respond to the study drugs.

There are now several HIV treatment options for a person with HIV infection who has not yet
been treated. Most people who receive treatment and take their medications as directed have a
good result. This is usually determined by measuring the amount of HIV in the blood (viral
load). The best response is when HIV cannot be found (less than 50 copies/mL) in the blood.
However, it has recently become clear that some people with HIV who are receiving effective
HIV drugs continue to have more health problems than people without HIV infection. Sometimes,
there is damage to organs in the body, including bone, kidneys, and the brain.

Inclusion Criteria:

- HIV-1 infection

- No evidence of exclusionary resistance mutations defined as evidence of any major NRTI
mutation according to the current IAS list of HIV-1 Resistance Mutations Associated
with Drug Resistance, or any DRV RAMs (refer to the A5303 PSWP for a list of these
mutations) on any genotype; or evidence of significant NRTI or DRV resistance on any
phenotype performed at any time prior to study entry. NNRTI-associated resistance
mutations were not exclusionary.

- ARV drug-naïve, defined as in the instances defined in section 4.1.3 of the protocol.

- R5-only tropism based on Trofile testing performed within 90 days prior to study
entry.

- Screening HIV-1 RNA >1000 copies/mL obtained within 90 days prior to study entry by
any FDA-approved test for quantifying HIV-1 RNA at any laboratory that has a CLIA
certification or its equivalent.

- Known hepatitis C virus (HCV) antibody status (performed at any laboratory that had a
CLIA certification or its equivalent).

- Certain laboratory values obtained within 60 days prior to study entry, as defined in
section 4.1.7 of the protocol.

- For women of reproductive potential, negative serum or urine pregnancy test with a
sensitivity of ≤25 mIU/mL within 72 hours prior to study entry.

- Female subjects of reproductive potential, who were participating in sexual activity
that could lead to pregnancy, must agree to use at least one reliable method of
contraception (as defined in section 4.1.9.1 of the protocol) while receiving the
study drugs and for 6 weeks after stopping the medications.

- Female subjects who were not of reproductive potential or whose male partner(s) had
azoospermia were eligible to take study drugs without the use of contraceptives.

- Ability and willingness of subject or legal guardian/representative to give written
informed consent.

- Willingness to undergo neuropsychological testing.

- DXA scan performed after confirmation of the subject's eligibility by Trofile testing
but no more than 4 weeks prior to randomization.

Exclusion Criteria:

- Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine,
systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to
study entry.

- New use of hormonal therapies within 6 months prior to study entry. (Stable therapy
for ≥6 months was permitted.)

- New use of oral contraceptive pills (OCPs) in the past 3 months. (Stable therapy for
≥3 months was permitted.)

- Any oral, intravenous, or inhaled steroids within 30 days prior to study entry.
(Intranasal steroids and topical corticosteroids were allowed.)

- Known allergy/sensitivity to study drugs or their formulations. (A history of sulfa
allergy was not an exclusionary condition.)

- Known hypersensitivity to soy lecithin.

- Serious illness requiring systemic treatment and/or hospitalization until subject
either completes therapy or was clinically stable on therapy, in the opinion of the
site investigator, for at least 7 days prior to study entry. (Oral candidiasis,
vaginal candidiasis, mucocutaneous herpes simplex, and other minor illnesses (as
judged by the site investigator) were not exclusionary conditions.)

- Requirement for any current medications that were prohibited with any study drugs.
(Prohibited medications must be discontinued at least 30 days prior to entry. Refer to
the A5303 PSWP for a list of prohibited medications.)

- The presence of decompensated cirrhosis.

- A history of or current, active HBV infection defined as positive hepatitis B surface
antigen test (or positive HBV DNA in subjects with isolated HBcAb positivity, defined
as negative HBsAg, negative HBsAb, and positive HBcAb) at screening.

- Current or prior use of biphosphonates, teriparatide, raloxifene, or denosumab.

- Weight >300 lbs (exceeds weight limit of DXA scanners).

- History after 18 years of age of fracture of the spine, hip, wrist, or other site
thought to be related to osteoporosis or bone fragility.

- Currently breastfeeding.

- Any active psychiatric illness including schizophrenia, severe depression, or severe
bipolar affective disorder that, in the opinion of the investigator, could confound
the analysis of the neurological examination or neuropsychological test results.

- Active drug or alcohol abuse that, in the investigator's opinion, could prevent
compliance with study procedures or confound the analysis of study endpoints.

- Active brain infection (except for HIV-1), fungal meningitis, toxoplasmosis, central
nervous system (CNS) lymphoma, brain neoplasm, or space-occupying brain lesion
requiring acute or chronic therapy.
We found this trial at
38
sites
Seattle, Washington 98104
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Atlanta, Georgia 30308
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Baltimore, Maryland 21201
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Baltimore, Maryland 21205
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Birmingham, Alabama 35294
1785
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Boston, Massachusetts 02115
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02114
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Camden, New Jersey 08103
2377
mi
from 91732
Camden, NJ
Click here to add this to my saved trials
Chapel Hill, North Carolina 27514
2194
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Chicago, Illinois 60611
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60612
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45267
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Cleveland, Ohio 44106
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Cleveland, Ohio 44109
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
1960
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75215
1226
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
818
mi
from 91732
Denver, CO
Click here to add this to my saved trials
Greensboro, North Carolina 27401
2151
mi
from 91732
Greensboro, NC
Click here to add this to my saved trials
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
1358
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90095
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90033
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
1586
mi
from 91732
Memphis, TN
Click here to add this to my saved trials
Miami, Florida 33139
2320
mi
from 91732
Miami, FL
Click here to add this to my saved trials
Nashville, Tennessee 37204
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
2351
mi
from 91732
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Providence, Rhode Island 02906
2562
mi
from 91732
Providence, RI
Click here to add this to my saved trials
Rochester, New York 14642
2245
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
2244
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Saint Louis, Missouri 63110
1573
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
San Diego, California 92103
105
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
San Francisco, California 94110
355
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
San Juan, 00935
3356
mi
from 91732
San Juan,
Click here to add this to my saved trials
2136
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Washington, District of Columbia 20007
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Washington, District of Columbia 20010
2281
mi
from 91732
Washington,
Click here to add this to my saved trials